Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Mitochondrial dysfunctions are central players in Alzheimer's disease (AD). In addition,
impairments in mitophagy, the process of selective mitochondrial degradation by autophagy …

Novel targets to arrest neurodegeneration in several dementing conditions involving
misfolded protein accumulations may be found in the diverse signaling pathways of the …

Neurodegenerative disorders of ageing (NDAs) such as Alzheimer disease, Parkinson
disease, frontotemporal dementia, Huntington disease and amyotrophic lateral sclerosis …

Aging has been targeted by genetic and dietary manipulation and by drugs in order to
increase lifespan and health span in numerous models. Metformin, which has demonstrated …

Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly.
It is characterized by a progressive and irreversible loss of cognitive abilities and formation …

In 1975, tau protein was isolated as a microtubule-associated factor from the porcine brain.
In the previous year, a paired helical filament (PHF) protein had been identified in …

This systematic review investigated whether the insulin sensitiser metformin has a
geroprotective effect in humans. Pubmed and Embase were searched along with databases …

INTRODUCTION RNA cleavage and phosphorylation-dephosphorylation of the RNA
polymerase II (Pol II) C-terminal domain (CTD) are two regulatory mechanisms of …

Metformin is the most commonly prescribed drug for type 2 diabetes mellitus. In recent years,
in addition to glucose lowering, several studies have presented evidence suggesting some …